Noopept is one of the newer nootropics. It was patented in the United States in 1995. Although it is sold as a dietary supplement in the U.S., in other countries it is used as a prescription nootropic. It is generally regarded as having an excellent safety profile and many people find it to be more effective than other nootropics.
What are some of the benefits of Noopept?
- ⇒ Improved Learning
- ⇒ Enhanced Memory
- ⇒ Reduced Anxiety
- ⇒ Reduced Depression
- ⇒ Improved Reflexes
- ⇒ Improvement in Overall Cognitive Performance
While Noopept is technically not a racetam, it is derived from the racetam family. Noopept is approximately 1000 times more potent than the well known racetam, Piracetam. This means that much smaller doses are needed to get the desired results. Like all nootropics, the exact mechanisms by which Noopept exerts its cognitive and mood boosting effects is not totally understood. It is thought to work like the racetams, by affecting NDMA and AMPA receptors in the brain. Noopept is thought to improve the function of the neurotransmitter acetylcholine, which is known to play a vital role in learning and memory.
When taken at the recommended dosages, Noopept is generally considered to be very safe. Several animal studies have shown that Noopept is actually neuroprotective. However, due to the small dosages needed for its nootropic benefits, extreme caution must be taken when measuring out a dose. Overdose is more likely with Noopept then with the racetams. Symptoms of overdose may include headaches, nausea, fatigue, and stomach problems. If you experience any of these symptoms it is advised that you stop taking Noopept and see your doctor. As with all supplements, you should consult with your physician before starting any new supplements.
The recommended dosage of Noopept is 10-40mg. It is always a good idea to start at the lowest dose and work your way up if necessary. Many people find that 10-20mg is enough to experience the benefits of Noopept.
 Solntseva EI, Bukanova JV, Ostrovskaya RU, Gudasheva TA, Voronina TA, Skrebitsky VG (1997). “The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels”. General Pharmacology 29 (1): 85–99.
 Ostrovskaia RU, Gudasheva TA, Voronina TA, Seredenin SB (2002). “The original novel nootropic and neuroprotective agent noopept”. Eksperimentalnaia i klinicheskaia farmakologiia (in Russian) 65 (5): 66–72.
 Ostrovskaya RU, Romanova GA, Barskov IV, Shanina EV, Gudasheva TA, Victorov IV, Voronina TA, Seredenin SB (1999). “Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model”.Behavioural Pharmacology 10 (5): 549–553.
 Pelsman A, Hoyo-Vadillo C, Gudasheva TA, Seredenin SB, Ostrovskaya RU, Busciglio J (2003). “GVS-111 prevents oxidative damage and apoptosis in normal and Down’s syndrome human cortical neurons”. International Journal of Developmental Neuroscience 21 (3): 117–124.